1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J]. CACancerJClin, 2007, 57:43.
2Janzen NK, Kin HL, Figlin RA, et al. Surveillance after radical or partial nephretomy for localized renal cell carcinoma and management of recurrent disease [J]. Urol Clin North Am, 2003, 30 : 843.
3Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma: Current treatment options [ J ]. Oncology, 2003, 4:385.
4Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 - 9006 in patients with advanced refractory solid tumors [J]. J Clin Oncol, 2005, 23 (5) :965.
5Escudier B, Eisen T, Bukowski RM, et al. Sorafenib in advanced clear- cell carcinoma [J]. N Engl J Med, 2007, 356 (2) : 125.
2Zhang HL, Dong BJ, Lu JJ, et al. Effi-cacy of sorafenib on metastatic renal cellcarcinoma in Asian patients : results froma multicenter study. BMC Cancer,2009,9: 249.
